Tetramethyltetraazabicyclooctanedione (Tetramethyltetraazabicyclooctandionum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Anxiolytics

Included in the formulation
  • Adaptol
    pills inwards 
    Olainfarm, AO     Latvia
    • АТХ:

    N.05.B.X   Other anxiolytics

    Pharmacodynamics:Anxiolytic agent, close in chemical structure to natural metabolites of the body (derivative of bicyclic biocompounds). It acts on the activity of the structures entering the limbic-reticular complex, in particular, on the emotionogenic zones of the hypothalamus, and also affects all the main neurotransmitter systems are GABA-, choline-, serotonin- and adrenergic, promoting their balance and integration. Does not show central and peripheral anticholinergic properties, does not exert peripheral adrenoblocking action.

    Eliminates or reduces anxiety, anxiety, fear, internal emotional tension and irritability. Soothing effect is not accompanied by muscle relaxation and violation of coordination of movements. It does not reduce mental and motor activity, it can be applied during the working day. Does not create an upbeat mood and a sense of euphoria, does not cause addiction and dependence.

    Has nootropic effect, improves cognitive functions, attention and mental performance, without stimulating the symptoms of productive psychopathological disorders (delirium, pathological emotional activity).

    Regulates disturbed sleep at night, facilitates falling asleep, normalizes the structure of sleep. Without giving a direct hypnotic effect, increases the effect of hypnotics.

    It alleviates or removes nicotine abstinence, weakens craving for alcohol and psychoactive substances.

    Promotes improvement of myocardial trophism (due to increased coronary blood flow), increases the strength of heartbeats, normalizes the permeability of the vascular wall, reduces blood viscosity, reduces intravascular aggregation of erythrocytes.

    Pharmacokinetics:After oral intake is well absorbed from the digestive tract (77-80%). The maximum concentration of active substance in the blood plasma is reached after 0.5 h after administration. The high concentration of the active substance persists for 3-4 hours, then gradually decreases. Up to 40% of the dose is associated with erythrocytes. The remaining part does not bind to plasma proteins and is in the blood plasma in a free form, so the active substance is unrestrictedly distributed throughout the body and freely overcomes the cell membranes.

    The active substance is not metabolized and does not accumulate in the body.

    About 55-70% of the dose taken within 24 hours is excreted from the body with urine, the rest - with feces in unchanged form.

    Indications:Neuroses and neurosis-like conditions that develop as a result of exhausting psychoemotional, neuropsychic and physical loads (irritability, emotional instability, anxiety, fear), anxiety-paranoid syndrome in schizophrenia, involutional and vascular psychoses; chronic verbal hallucinosis of organic genesis; cardialgia of various genesis, IHD, rehabilitation after myocardial infarction (as part of complex therapy); improving the tolerability of neuroleptics and tranquilizers (elimination of somato-vegetative and neurological side effects caused by them); reduction of desire: to smoking tobacco, drinking alcohol, psychoactive substances (as part of complex therapy).

    ICD-10

    V.F10-F19.F10   Mental and behavioral disorders caused by alcohol use

    V.F10-F19.F11   Mental and behavioral disorders caused by the use of opioids

    V.F10-F19.F13   Mental and behavioral disorders caused by the use of sedatives or hypnotics

    V.F10-F19.F17   Mental and behavioral disorders caused by tobacco use

    V.F10-F19.F19   Mental and behavioral disorders caused by the simultaneous use of several drugs and the use of other psychoactive substances

    V.F20-F29.F20   Schizophrenia

    V.F20-F29.F21   Chrysotile disorder

    V.F20-F29.F22   Chronic delusional disorders

    V.F20-F29.F23   Acute and transient psychotic disorders

    V.F20-F29.F25   Schizoaffective disorder

    V.F20-F29.F28   Other Inorganic Psychotic Disorders

    V.F20-F29.F29   Inorganic psychosis, unspecified

    V.F30-F39.F30.0   Hypomania

    V.F40-F48.F40   Phobic anxiety disorders

    V.F40-F48.F40.8   Other phobic anxiety disorders

    V.F40-F48.F42   Obsessive-compulsive disorder

    V.F40-F48.F43   Reaction to severe stress and adaptation disorders

    V.F40-F48.F45.3   Somatoform dysfunction of the autonomic nervous system

    V.F40-F48.F48.8   Other specified neurotic disorders

    V.F40-F48.F48.0   Neurasthenia

    V.F60-F69.F60.3   Emotionally unstable personality disorder

    IX.I20-I25.I20   Angina pectoris [angina pectoris]

    IX.I20-I25.I21   Acute myocardial infarction

    IX.I20-I25.I25.2   Postponed myocardial infarction

    XVIII.R00-R09.R07.2   Pain in the region of the heart

    XVIII.R40-R46.R45.0   Nervousness

    XVIII.R40-R46.R45.1   Anxiety and Excitement

    XVIII.R40-R46.R45.4   Irritability and anger

    Contraindications:Hypersensitivity, pregnancy (I trimester) and the period of breastfeeding, children under 10 years.

    Carefully:Be careful when appointing patients with a tendency to hypotension, kidney and liver diseases.

    Pregnancy and lactation:Adequate and well-controlled studies in humans and animals have not been conducted. It should be taken into account that the active substance penetrates well into all body fluids, including amniotic fluid and breast milk. In this regard, use during pregnancy and during breastfeeding is contraindicated.

    Action category for the fetus by FDA - not determined.

    Dosing and Administration:Inside, regardless of food intake, 0.3-1.0 g 2-3 times a day. The maximum single dose of 3 grams, daily - 10 g. The course of treatment from several days to 2-3 months, with mental illness - up to 6 months.

    As a means of reducing the craving for tobacco smoking, drinking alcohol and psychoactive substances (as part of complex therapy), use 0.5-1 g 3 times a day, the course - 5-6 weeks.

    Side effects:Rarely - dizziness, decreased blood pressure, dyspeptic disorders, allergic reactions (skin rash, itching); when used in high doses - bronchospasm, lower body temperature, weakness.

    Overdose:The toxicity is low, the typical clinical picture of an overdose is absent. Serious poisoning is not registered. Sometimes the following symptoms can be observed: weakness, arterial hypotension, dizziness. If you suspect an overdose, you should take symptomatic therapy, wash your stomach.

    Interaction:When used simultaneously with benzodiazepine tranquilizers enhances their effect and reduces the risk of side effects.

    When used simultaneously with antipsychotics enhances their effect and reduces the risk of side effects.

    Strengthens the action antidepressants, improves their tolerability.

    Enhances the effect sleeping pills and narcotic drugs.

    When used simultaneously with propranolol helps to reduce its atherogenic effect.

    Special instructions:Addiction, dependence (mental and physical), withdrawal symptoms are not established.

    With lowering blood pressure and / or body temperature (possibly at 1-1.5 ° C), no stopping is required (these parameters are normalized on their own).

    If allergic reactions occur, the application should be discontinued.

    During the treatment period, care must be taken when driving vehicles and when engaging in potentially dangerous activities requiring increased concentration of attention and speed of psychomotor reactions.

    Instructions
    Up